Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review.

Authors:

Claudia Rutherford Manish I Patel Margaret-Ann Tait David P Smith Daniel S J Costa Madeleine T King

Support Care Cancer 2018 Apr 1;26(4):1061-1076. Epub 2018 Feb 1.

Quality of Life Office, Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney, Level 6 North, Chris O'Brien Lifehouse C39Z, Sydney, NSW, 2006, Australia.

Objective: Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring ongoing treatment and endoscopic examinations that are frequent and can be life-long. To ensure the comprehensive assessment of the benefits and harms of treatments for NMIBC, the impact on important and relevant patient-reported outcomes (PROs) should be determined. We systematically reviewed the NMIBC PRO literature to determine the suitability of available PRO measures (PROMs) for use in evaluating patient outcomes in NMIBC research.

Methods: We searched six electronic databases, reference lists, and key authors. Two reviewers independently applied inclusion and quality criteria and extracted findings. PROM domains, item content, and content coverage and relevance were determined for identified PROMs. Content validity was assessed against an empirically derived NMIBC-specific conceptual framework that includes 11 PRO domains and 19 sub-domains.

Results: Seventeen studies assessed PROs related to NMIBC and treatment impact. From these studies, 11 PROMs were identified, including three generic, three cancer-specific, and five symptom-specific. None of the PROMs cover all PRO domains important in NMIBC as assessed against our conceptual framework. The EORTC QLQ-C30 plus the NMIBC24 module was best aligned to the conceptual model, but failed to represent six outcomes important to NMIBC patients.

Conclusions: Currently, some outcomes important in NMIBC are inadequately covered by generic and cancer-specific measures despite similar conceptual models. This review identified gaps in the literature regarding assessment of symptoms and other PROs considered important by NMIBC patients. Careful consideration of PROM item content is required when selecting outcome measures for use in future NMIBC clinical trials to ensure that appropriate measures are used to assess outcomes that matter to patients.

Download full-text PDF	Source
http://dx.doi.org/10.1007/s00520-018-4058-8	DOI Listing

April 2018

Publication Analysis

Top Keywords

reviewers independently

nmibc24 module

qlq-c30 nmibc24

independently applied

Keyword Occurance

Similar Publications

Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.

Eur Urol Open Sci 2022 May 1;39:14-21. Epub 2022 Apr 1.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Background: Radical cystectomy (RC) is indicated in primary or secondary muscle-invasive bladder cancer (primMIBC, secMIBC) and in primary or recurrent high- or very high-risk non-muscle-invasive bladder cancer (primHR-NMIBC, recHR-NMIBC). The optimal timing for RC along the disease spectrum of nonmetastatic urothelial carcinoma remains unclear.

Objective: To compare outcomes after RC between patients with primHR-NMIBC, recHR-NMIBC, primMIBC, and secMIBC. Read More

View Article and Full-Text PDF

May 2022

Similar Publications

Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer.

Authors:

Ali Hamade Deyang Li Kathrin Tyryshkin Minqi Xu Gwenaelle Conseil Priyanka Yolmo Jake Hamilton Stephen Chenard D Robert Siemens Madhuri Koti

Biol Sex Differ 2022 May 3;13(1):19. Epub 2022 May 3.

Queen's Cancer Research Institute, Kingston, ON, Canada.

Sex and age associated differences in the tumor immune microenvironment of non-muscle invasive bladder (NMIBC) cancer and associated clinical outcomes are emerging indicators of treatment outcomes. The incidence of urothelial carcinoma of the bladder is four times higher in males than females; however, females tend to present with a more aggressive disease, a poorer response to immunotherapy and suffer worse clinical outcomes. Recent findings have demonstrated sex differences in the tumor immune microenvironment of non-muscle invasive and muscle invasive bladder cancer and associated clinical outcomes. Read More

View Article and Full-Text PDF

May 2022

Similar Publications

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.

J Clin Invest 2022 May 3. Epub 2022 May 3.

Department of Therapeutic Innovation and Early Trials, Gustave Roussy, Villejuif, France.

Patients with high-risk non muscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical BCG therapy and may have a dismal outcome. Resistance mechanisms to such immunotherapy remain misunderstood. Here, using cancer cell lines, freshly resected human bladder tumors and cohorts of bladder cancer patients pre- and post-BCG therapy, we demonstrate two distinct patterns of immune subversion upon BCG relapse. Read More

View Article and Full-Text PDF

May 2022

Similar Publications

Real-World Outcomes Driving the Needle Toward Simplification of NMIBC Risk-Stratification.

Authors:

Heather L Huelster Wade J Sexton

J Urol 2022 May 2:101097JU0000000000002731. Epub 2022 May 2.

H Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

View Article and Full-Text PDF

May 2022

Similar Publications

STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.

Authors:

Naheema S Gordon Nada Humayun-Zakaria Anshita Goel Ben Abbotts Maurice P Zeegers K K Cheng Nicholas D James Roland Arnold Richard T Bryan Douglas G Ward

Eur Urol Open Sci 2022 Apr 4;38:88-95. Epub 2022 Mar 4.

Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Background: Mutations in cause complete loss of STAG2 protein in approximately one-third of non-muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that loss of STAG2 expression is a good prognostic indicator in NMIBC.

Objective: To confirm the relationship between protein expression and clinical outcomes and tumour characteristics in NMIBC. Read More

View Article and Full-Text PDF

April 2022

Similar Publications

}

Search Our Scientific Publications & Authors